Conference ReCAP

Highlights in Early-Stage Non–Small Cell Lung Cancer From ASCO 2022


 

Highlights in early-stage non–small lung cancer (NSCLC) from the 2022 American Society of Clinical Oncology Annual Meeting are discussed by Dr Jack West of City of Hope Comprehensive Cancer Center in Duarte, California.

He opens with a post hoc analysis of CheckMate 816, which showed that achieving a pathologic complete response with adjuvant nivolumab plus chemotherapy was highly associated with improved event-free survival.

Next, Dr West reports on early results from the NADIM II trial, which confirmed the superiority of neoadjuvant nivolumab plus chemotherapy in resectable stage IIIa NSCLC, as well as the need for careful patient selection.

He moves on to describe the neoSCORE study, which compared two vs three cycles of neoadjuvant sintilimab plus chemotherapy, with the latter achieving a markedly higher major pathologic response rate.

Dr West next examines two interventional studies, starting with an analysis of the SEER database, which showed that addition of radiation therapy to neoadjuvant chemotherapy does not offer a benefit. He ends with a Veterans Affairs study underlining the importance of surgical quality as a predictor of patient outcomes.

--

Associate Professor, Department of Medical Oncology, City of Hope Comprehensive Cancer Care, Duarte, California; Medical Director, AccessHope, Los Angeles, California

Howard (Jack) West, MD, has disclosed the following relevant financial relationships:

Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Amgen; AstraZeneca; Eli Lily; EQRx; Genentech/Roche; Merck; Mirati; Pfizer; Regeneron; Takeda

Serve(d) as a speaker or a member of a speakers bureau for: AstraZeneca; Merck

Recommended Reading

Similar prognosis in pregnant vs. nonpregnant BC patients receiving chemotherapy
MDedge Hematology and Oncology
ER+/HER2− BC: Age and Ki-67 index predict nodal response to NAC
MDedge Hematology and Oncology
Patients with blood cancers underutilize palliative care
MDedge Hematology and Oncology
$3 billion in cancer drug waste: Can it be salvaged?
MDedge Hematology and Oncology
Roe v. Wade overturned, ending 50 years of abortion protections
MDedge Hematology and Oncology
Evidence still lacking that vitamins prevent CVD, cancer: USPSTF
MDedge Hematology and Oncology
$150K: Average industry payment to top 1% of oncologists
MDedge Hematology and Oncology
FDA approves liso-cel as second-line therapy for LBCL
MDedge Hematology and Oncology
Artificial intelligence colonoscopy system shows promise
MDedge Hematology and Oncology
Adjuvant vs. neoadjuvant? What has ASCO 2022 taught us regarding resectable NSCLC?
MDedge Hematology and Oncology